Adding to yesterday’s announcement of a $1.26 billion investment in Dublin, the company said it plans to match that investment to expand its Puurs, Belgium manufacturing site.
The investment to expand manufacturing at Pfizer’s plant in Dublin would double its capacity to produce key substances used in biological drugs.
Moderna Inc. said its Omicron-tailored vaccines produced a better immune response against the BA.4/5 subvariants in a mid-to-late stage study, when given as a booster dose, compared with its original shot.
AstraZeneca will give up on seeking approval for its COVID-19 vaccine in the United States, the company announced during its third-quarter report. It is also abandoning three early-stage programs.
COVID-19 vaccine maker BioNTech on Monday raised the lower bound of its 2022 COVID-19 vaccine revenue guidance for the full year, citing demand for its adapted shots and higher prices.
Pfizer Inc. expects to roughly quadruple the price of its COVID-19 vaccine to about $110 to $130 per dose after the United States government’s current purchase program expires, Pfizer executive Angela Lukin said on Thursday.
Moderna Inc. (MRNA.O) has agreed to provide its new variant-adapted COVID-19 vaccine to the global scheme aiming to deliver shots to the world’s poorest people.
Attempts by Oxford University researchers and AstraZeneca Plc to create a nasal-spray version of their jointly developed COVID-19 shot suffered a setback on Tuesday as initial testing on humans did not yield the desired protection.
2022 has been marked by the first year of leadership under CEO Joaquin Duato and the anticipated separation of the company’s consumer health business.
A Pfizer executive with a lead role in negotiating a COVID-19 vaccine bulk supply agreement with the European Commission said she “categorically” rules out that the U.S. drugmaker’s chief executive agreed the contract via mobile phone text messages.